Completed PHASE2 INTERVENTIONAL 3-arm NCT00737100

Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

A Randomized, Double-blind, Placebo-controlled Parallel Group Study to Investigate the Safety and Efficacy of Two Doses of Tiotropium Bromide (2.5 mcg and 5 mcg) Administered Once Daily Via the Respimat Device for 12 Weeks in Patients With Cystic Fibrosis.

Sponsor: Boehringer Ingelheim

Conditions Cystic Fibrosis

Interventions Placebo Respimat Tiotropium bromide 5 mcg tiotropium bromide-low dose-2.5mcg

Updated 6 times since 2017 Last updated: May 7, 2014 Started: Sep 30, 2008 Primary completion: Apr 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Cystic Fibrosis and is currently completed. Boehringer Ingelheim leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boehringer Ingelheim

Data source: Boehringer Ingelheim

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adelaide, Australia , Amiens, France , Ancona, Italy , Angers, France , Ann Arbor, United States , Belfast, United Kingdom , Birmingham, United Kingdom , Boston, United Kingdom , Bron, France , Brussels, Belgium and 67 more locations